All In Biotech

Drug Trial Radar · NCT05481151

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

A Phase IIIb, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-njft (P1101) in Adult Patients With Polycythemia Vera (PV)

Last checked: Nov 20, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 111 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

111

Actual

Start

Oct 26, 2022

Primary completion

Jun 30, 2025

Study completion Jul 31, 2027

Sponsor

Lead sponsor
PharmaEssentiaIndustry
Sponsor type
Industry
First posted
Aug 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV

Conditions

  • Polycythemia Vera

Interventions

  • P1101 (Ropeginterferon alfa-2b-njft)Drug

    Ropeginterferon alfa-2b-njft

  • Ropeginterferon alfa-2b-njft (P1101)Drug

    Ropeginterferon alfa-2b-njft

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare efficacy, safety, and tolerability of P1101 utilizing 250-350-500 mcg compared to the current labeled dosing through assessing the proportion of subjects that are in a complete hematologic response at Week 24.Time frame: 24 weeks

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • Baptist MD Anderson

    Jacksonville, Florida

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana

  • University of Kansas Medical Center

    Westwood, Kansas

  • Mercy Health

    Paducah, Kentucky

  • Tulane University Medical Center

    New Orleans, Louisiana

  • American Oncology Partners of Maryland PA (Center for Cancer & Blood Disorders)

    Bethesda, Maryland

  • Washington University School of Medicine

    St Louis, Missouri

  • Astera HealthCare

    East Brunswick, New Jersey

  • Mount Sinai

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • University of North Carolina Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina

  • East Carolina University

    Greenville, North Carolina

  • Wake Forest Baptist Medical Center

    High Point, North Carolina

  • University of Tennessee Health Science Center

    Memphis, Tennessee

  • MD Anderson

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

  • University of Virginia - Emily Couric Cancer Center

    Charlottesville, Virginia

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • St. Paul's Hospital

    Vancouver, British Columbia, Canada

  • Juravinski Cancer Center - Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • The Ottawa Hospital

    Ottawa, Ontario, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.